Histidine-Rich Glycoprotein Inhibits High-Mobility Group Box-1-Mediated Pathways in Vascular Endothelial Cells through CLEC-1A

HIGHLIGHTS
HRG inhibited LPS-induced HMGB1 translocation and release from endothelial cells
HRG reduced inflammatory responses in endothelial cells caused by released HMGB1
CLEC-1A was identified as the receptor for the function of HRG on endothelial cells

Gao et al., iScience 23, 101180
June 26, 2020 © 2020 The Authors.
https://doi.org/10.1016/j.isci.2020.101180
Histidine-Rich Glycoprotein Inhibits High-Mobility Group Box-1-Mediated Pathways in Vascular Endothelial Cells through CLEC-1A

Shangze Gao, 1 Hidenori Wake, 1 Masakiyo Sakaguchi, 2 Dengli Wang, 1 Youhei Takahashi, 1 Kiyoshi Teshigawara, 1 Hui Zhong, 1 Shuji Mori, 3 Keyue Liu, 1 Hideo Takahashi, 4 and Masahiro Nishibori 1, 5, *

SUMMARY

High-mobility group box-1 (HMGB1) protein has been postulated to play a pathogenic role in severe sepsis. Histidine-rich glycoprotein (HRG), a 75 kDa plasma protein, was demonstrated to improve the survival rate of septic mice through the regulation of neutrophils and endothelium barrier function. As the relationship of HRG and HMGB1 remains poorly understood, we investigated the effects of HRG on HMGB1-mediated pathway in endothelial cells, focusing on the involvement of specific receptors for HRG. HRG potently inhibited the HMGB1 mobilization and effectively suppressed rHMGB1-induced inflammatory responses and expression of all three HMGB1 receptors in endothelial cells. Moreover, we first clarified that these protective effects of HRG on endothelial cells were mediated through C-type lectin domain family 1 member A (CLEC-1A) receptor. Thus, current study elucidates protective effects of HRG on vascular endothelial cells through inhibition of HMGB1-mediated pathways may contribute to the therapeutic effects of HRG on severe sepsis.

INTRODUCTION

High-mobility group box-1 (HMGB1), a nonhistone chromatin-binding nuclear protein, can be actively secreted into the extravascular space by several immune cell types or passively released by damaged tissues and necrotic cells (DeMarco et al., 2005; Andersson et al., 2000). A high concentration of HMGB1 in the plasma of patients with severe sepsis correlates with a poor prognosis and high mortality, and the pharmacologic inhibition of HMGB1 improved survival in animal models of acute inflammation and severe sepsis (Chen et al., 2004). Systemic inflammation is one of the hallmarks of septic shock, and the disorder of microvascular endothelium appears to produce the amplification of these inflammatory responses (Kirkpatrick et al., 1997). Thus, microvascular injury is one of the characteristics of sepsis-associated tissue damage that may be manifested by single or multiple organ failure syndromes (Lehr et al., 2000; Lentsch and Ward, 2000). HMGB1 was reported to have multiple proinflammatory effects on vascular endothelial cells by binding to three pathogen-associated cell surface pattern recognition receptors, thereby inducing tumor necrosis factor alpha (TNF-α) expression and NF-κB activation in target cells and stimulating the production of an array of proinflammatory cytokines (Abraham et al., 2000; Park et al., 2004; Lotze and Tracey, 2005; Fiuza et al., 2003; Treutiger et al., 2003; Mullins et al., 2004), which suggest an important role for HMGB1 in endothelial cell activation and injury in sepsis and systemic inflammation.

Histidine-rich glycoprotein (HRG) is an abundant plasma protein (60–100 μg/mL) synthesized in liver, which can regulate many biological processes such as angiogenesis, coagulation, and the phagocytosis of apoptotic cells through the interaction with various ligands (Koide et al., 1986; Ronca and Raggi, 2015; Poon et al., 2011). Shannon et al. proved that HRG decreased the mortality of a septic mouse model with S pyogenes-induced abscesses by killing and trapping bacteria in the abscess sites (Shannon et al., 2010). Wake et al. reported that HRG prevents septic lethality through the regulation of neutrophils and vascular endothelial cells (Wake et al., 2016). A counteracting role of HRG on damage-associated molecular pattern/pathogen-associated molecular pattern (DAMP/PAMP)-induced responses has long been recognized (Wake et al., 2009, 2016; Gao et al., 2019; Zhong et al., 2018). In recent clinical studies, HRG was also proposed as a new biomarker to predict the outcome of sepsis patients (Kuroda et al., 2018; Nishibori et al., 2018). However, the effect of HRG on HMGB1 release or HMGB1 signaling has never been
HRG Inhibited LPS-induced HMGB1 Translocation and Release in EA.hy926 Cells

In present study, we firstly proved that the inhibitory effects of HRG on lipopolysaccharide (LPS)-induced HMGB1 translocation and HMGB1-induced signal pathway were mediated through the stimulation of specific receptors of CLEC-1A on vascular endothelial cells. Our results strongly suggest that the inhibition of HMGB1 action by HRG may contribute to HRG’s mortality-reducing protective activity against severe sepsis, and our findings also further explained the mechanism underlying the regulation of neutrophils and endothelium barrier function by HRG under septic conditions in vivo and in vitro (Wake et al., 2016; Gao et al., 2019). This demonstration of an intimate relationship between HRG and HMGB1 provides direct supporting evidence for the supplementary treatment of sepsis with HRG.

RESULTS

HRG Inhibited LPS-induced HMGB1 Translocation and Release in Endothelial Cells

Several studies showed that HMGB1 can be released from human endothelial cells in response to both endotoxin and TNF-α (Fiuza et al., 2003; Treutiger et al., 2003; Mullins et al., 2004). EA.hy926 is a transformed cell line, established by fusing primary human umbilical vein endothelial cells with a thioguanine-resistant clone of A549, carcinoma of human alveolar epithelial cell. Our results showed that LPS actively induced HMGB1 translocation from EA.hy926 cells in a concentration- and time-dependent manner (Figure 1A), whereas HRG inhibited this process in a concentration-dependent manner (Figure 1B, left panel). However, HSA, a major plasma protein, did not show any inhibitory effects at the same concentration (1 μmol/L). In addition, HRG did not show any influence on HMGB1 translocation in the absence of LPS (Figure 1B, right panel). These results were quantified with ImageJ software through the setting of a cutoff level of HMGB1 fluorescence in the cell nuclei (Figure 1C). HRG also inhibited the TNF-α-induced HMGB1 translocation in EA.hy926 cells (Figure S1). The inhibitory effect of HRG on LPS-induced HMGB1 translocation was also true in primary human lung microvascular endothelial cells (HMVECs, Figure S2).

To confirm these results, we also measured the HMGB1 content in nucleus, cytoplasma, and culture medium of endothelial cells with western blotting. The results showed that HRG not only inhibited HMGB1 translocation from nucleus to cytoplasm (Figure 1D) but also effectively suppressed HMGB1 release into extracellular space (Figure 1E). The cell viability assay also proved that the LPS stimulation triggered an active release of HMGB1 from EA.hy926 cells and both LPS (100 ng/mL) and rHMGB1 (1 μg/mL) were not...
toxic to the endothelial cells (Figure S3). In addition, HRG effectively inhibited the LPS-induced decrease in HMGB1 mRNA expression in both EA.hy926 cells and HMVECs (Figure S4).

HRG Suppressed the rHMGB1-Mediated Adhesive Molecule Expression and Neutrophil Adhesion

HMGB1 was reported to induce inflammatory responses by increasing the cell surface expressions of the cell adhesion molecules ICAM-1, VCAM-1, and E-selectin on the surface of endothelial cells, thereby promoting the adhesion and migration of leukocytes across the endothelium and to sites of inflamed tissues (Fiuza et al., 2003; Treutiger et al., 2003; Mullins et al., 2004). As presented in Figures 2A–2C, HRG effectively inhibited rHMGB1-induced expressions of ICAM-1 and VCAM-1. These effects of HRG were also observed in primary human lung microvascular endothelial cells (Figure S5).

As is well known, elevated expressions of adhesion molecules correlate well with the enhanced binding of neutrophils to endothelial cells and their subsequent migration. We therefore performed cell adhesion experiments using purified neutrophils and endothelial cell co-culture system. The results showed that HRG inhibited the adhesion of human neutrophils to both LPS- and rHMGB1-activated endothelial cells (Figures 2D and 2E).

HRG Prevented the rHMGB1-induced Inflammatory Responses

Cytokine overproduction is one of the major events in severe inflammatory responses. Released HMGB1 is known to interact with specific cell receptors to amplify inflammatory responses by inducing the expression of proinflammatory cytokines (Fiuza et al., 2003; Treutiger et al., 2003; Mullins et al., 2004). According to RT-PCR results in Figure 4A (upper panel), the 12-h incubation of EA.hy926 cells with different concentrations of rHMGB1 resulted in concentration-dependent expressions of TNF-α and NF-κB. HRG (1 μM) strongly inhibited rHMGB1 (1 μg/mL)-induced responses. In addition, HRG significantly inhibited the rHMGB1-induced increase in the expressions of IL-6, IL-8, and IL-1β (Figure 3A) and cytokine secretion in the culture medium (Figure 3B).

HMGB1 was reported to upregulate inflammatory pathways by activating NF-κB and promoting the expression of TNF-α by endothelial cells and monocytes (Andersson et al., 2000). As presented in Figure 4A, NF-κB/p65 was localized mainly in the cytoplasm in the non-stimulated control group, whereas in the rHMGB1-treated cells, NF-κB/p65 was translocated into the nuclei. Pretreatment with HRG clearly suppressed the rHMGB1-induced NF-κB/p65 translocation to nuclei in endothelial cells in immunostaining and western blotting (Figures 4A and 4B). The effects of HRG on the NF-κB activation were consistent with HRG’s effects on the rHMGB1-induced cytokine production.

HRG Downregulates the Expression of HMGB1 Receptors

The pro-inflammatory activity of rHMGB1 was reported to be mediated via its interaction and subsequent signaling through TLR2, TLR4, and RAGE (Park et al., 2004). As shown in Figure 4C, rHMGB1 induced the mRNA expression of all three receptors in endothelial cells by 1.7- to 2.4-fold, and HRG significantly inhibited the stimulatory effects of rHMGB1 on the expressions of TLR2, TLR4, and RAGE. Similar effects on their protein levels were also shown by western blotting (Figure 4D). These results demonstrated that one of the action mechanisms of HRG depends mainly on the suppression of the receptors’ overexpression on endothelial cells induced by rHMGB1.

HRG Inhibited HMGB1 Release and HMGB1-Mediated Inflammatory Responses In Vivo

To further confirm the relationship of HRG and HMGB1, we also examined the role of HRG on the regulation of HMGB1 release and rHMGB1-mediated signals in vivo. Previous study showed that plasma HRG
Figure 3. HRG Inhibited the rHMGB1-Stimulated Expression and Secretion of Proinflammatory Mediators in Endothelial Cells

EA.hy926 cells were cultured with rHMGB1 (1 μg/mL) for 12 h in the presence or absence of HRG (1 μM).

(A) The mRNA expressions of TNF-α, NF-κB, IL-1β, IL-6, and IL-8 in the cells were measured by quantitative RT-PCR. The results were normalized to the expression of β-actin and are expressed as the means ± SEM (n = 5 per group).

(B) Cell-free supernatants were harvested after 12-h stimulation with rHMGB1 to measure the concentrations of different proinflammatory cytokines by a CBA assay. The levels of IL-6, IL-8, and TNF-α in the culture media from each group are shown as the mean ± SEM (n = 5 per group). One-way ANOVA followed by the post hoc Fisher test. **p < 0.01 versus control, ##p < 0.01 and ++p < 0.01 vs. PBS and HSA.
In light of the multi-gene families of candidate receptors, we selected 18 genes (CLEC-1A, -1B, -2A, -2B, -2C, -2D, -4A, -4C, -4D, -4E, -4F, -4G, -4M, -5A, -6A, -7B, -12A, and -12B) from the CLEC family, two genes (TREM-1 and -4) from the TREM (triggering receptor expressed on myeloid cells) family, and five genes (SIGLEC-3, -5, -9, -14, -15) from the SIGLEC (sialic acid-binding Ig type lectin [SIGLEC]) family in accord with our interest in HRG binding. The individual genes were examined for HRG interaction. After the dual transfection of mAHRG with each receptor plasmid to HEK293T cells, we examined the mAHRG co-immunoprecipitates from the transfected cell lysates by western blotting to evaluate the potential binding of mAHRG with the foreign receptors. The results indicated that one event of interaction clearly occurred in the BIAcore sensograms of both exCLEC-1A-Fc and human recombinant exCLEC-1A protein to immobilized HRG. The results were quantified with ImageJ software. All results are means ± SEM of five different experiments. One-way ANOVA followed by the post hoc Fisher test. **p < 0.05 versus control, ***p < 0.05 and **p < 0.05 versus PBS and HSA.

**CLEC-1A Was Identified as the Receptor for HRG**

In light of the multi-gene families of candidate receptors, we selected 18 genes (CLEC-1A, -1B, -2A, -2B, -2C, -2D, -4A, -4C, -4D, -4E, -4F, -4G, -4M, -5A, -6A, -7B, -12A, and -12B) from the CLEC family, two genes (TREM-1 and -4) from the TREM (triggering receptor expressed on myeloid cells) family, and five genes (SIGLEC-3, -5, -9, -14, -15) from the SIGLEC (sialic acid-binding Ig type lectin [SIGLEC]) family in accord with our interest in HRG binding. The individual genes were examined for HRG interaction. After the dual transfection of mAHRG with each receptor plasmid to HEK293T cells, we examined the mAHRG co-immunoprecipitates from the transfected cell lysates by western blotting to evaluate the potential binding of mAHRG with the foreign receptors. The results indicated that one event of interaction clearly occurred in the screening trial using a CLEC family member, i.e., CLEC-1A (Figure 6A). We observed no appreciable interaction with the TREM or SIGLEC family members (data not shown). Collectively, these results prompted us to focus on CLEC-1A as a novel receptor for HRG.

The BIAcore sensograms of both exCLEC-1A-Fc and human recombinant exCLEC-1A protein to immobilized HRG showed a rapid increase in response units (RU), indicating the binding of both exCLEC-1A-Fc fusion protein and human recombinant exCLEC-1A protein to the immobilized HRG on the chip, followed by a decrease in the RU resulting from the dissociation of binding molecules upon washing. The binding of exCLEC-1A-Fc fusion protein and human recombinant exCLEC-1A protein to HRG was concentration dependent (Figures 6B and 6A). The equilibrium dissociation constant (K_D) was determined as 7 x 10^{-9} M and 4 x 10^{-7}, respectively. These results thus suggested a high-affinity binding of HRG to CLEC-1A. Meanwhile, when the exCLEC-1A-Fc fusion protein was immobilized on the CM5 sensor chip, the BIAcore sensogram of HRG to immobilized exCLEC-1A-Fc also showed a concentration-dependent increase in response units (Figure S6B). The equilibrium dissociation constant (K_D) was determined as 1 x 10^{-8} M. These results demonstrate a high-affinity binding of HRG to CLEC-1A in both directions.

**Blocking of CLEC-1A Neutralizes the Protective Activity of HRG on Neutrophils and Endothelial Cells**

It was reported that HRG (1 µmol/L) maintained the spherical shape of neutrophils, sustaining the rheological stability and preventing the unnecessary activation of vascular endothelial cells (Wake et al., 2016). We observed the morphological changes of the neutrophils under a fluorescent microscope at 60 min after incubation without a fixation procedure. Compared with the HBSS group, these neutrophils treated with HRG had a spherical shape, a loss of the irregularity of shapes, and shortened diameters. However, the spherical shape-inducing effects of HRG were significantly neutralized by the treatment with exCLEC-1A-Fc fusion protein (Figure 6C-a) or CLEC-1A Ab (Figure 6D-a), accompanied with increase of Form factor and cell area (Figures 6C-b and 6D-b).

The western blotting and RT-PCR results established that CLEC-1A was expressed in EA.hy926 cells. The expression level of CLEC-1A was not changed after stimulation with LPS (Figure 7A). The experiment results

![Figure 4. HRG Suppressed the rHMGB1-induced NF-κB Activation and Receptors Expressions in Endothelial Cells](image-url)
Figure 7 confirmed that the inhibitory effects of HRG on the LPS-induced HMGB1 translocation and rHMGB1-stimulated ICAM-1 expression in EA.hy926 cells were clearly neutralized by the pre-incubation with CLEC-1A Ab (10 mg/mL) for 6 h (Figures 7B and 7C). In addition, CLEC-1A or CLEC-1B Ab alone did not show any effects on the LPS-induced activation of endothelial cells (Figures 7B and 7C) or regulation of morphology changes of neutrophils (Figure 6D). These results provide evidence that CLEC-1A may be one of the receptors of HRG’s action on neutrophils and endothelial cells.

**DISCUSSION**

HMGB1 plays a novel inflammatory cytokine-like role that contributes to the lethality of sepsis, and neutralizing of HMGB1 release protected animals from the lethality of endotoxemia (Sama et al., 2004; Wang et al., 1999, 2001). The results presented herein together with those reported by others (Fiuza et al., 2003;
**A**

**STRs**

<table>
<thead>
<tr>
<th>KDa</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
<th>16</th>
<th>17</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>140</td>
<td>135</td>
<td>130</td>
<td>125</td>
<td>120</td>
<td>115</td>
<td>110</td>
<td>105</td>
<td>100</td>
<td>95</td>
<td>90</td>
<td>85</td>
<td>80</td>
<td>75</td>
<td>70</td>
<td>65</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>60</td>
<td>55</td>
<td>50</td>
<td>45</td>
<td>40</td>
<td>35</td>
<td>30</td>
<td>25</td>
<td>20</td>
<td>15</td>
<td>10</td>
<td>5</td>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IP: Anti-HA Ab  
IB: Anti-Flag Ab

**B**

**RU**

<table>
<thead>
<tr>
<th>Time (Sec)</th>
<th>0</th>
<th>200</th>
<th>400</th>
<th>600</th>
</tr>
</thead>
<tbody>
<tr>
<td>exCLEC 1A-Fc 3.125 µg/ml</td>
<td>0</td>
<td>50</td>
<td>100</td>
<td>150</td>
</tr>
<tr>
<td>exCLEC 1A-Fc 6.25 µg/ml</td>
<td>0</td>
<td>50</td>
<td>100</td>
<td>150</td>
</tr>
<tr>
<td>exCLEC 1A-Fc 12.5 µg/ml</td>
<td>0</td>
<td>50</td>
<td>100</td>
<td>150</td>
</tr>
<tr>
<td>exCLEC 1A-Fc 25 µg/ml</td>
<td>0</td>
<td>50</td>
<td>100</td>
<td>150</td>
</tr>
</tbody>
</table>

**C**

**exCLEC1A-Fc (µg/mL)**

<table>
<thead>
<tr>
<th>0</th>
<th>1 µg/mL</th>
<th>3 µg/mL</th>
<th>10 µg/mL</th>
<th>30 µg/mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBSS</td>
<td><img src="image1.png" alt="Image" /></td>
<td><img src="image2.png" alt="Image" /></td>
<td><img src="image3.png" alt="Image" /></td>
<td><img src="image4.png" alt="Image" /></td>
</tr>
<tr>
<td>HRG (0.25µM)</td>
<td><img src="image5.png" alt="Image" /></td>
<td><img src="image6.png" alt="Image" /></td>
<td><img src="image7.png" alt="Image" /></td>
<td><img src="image8.png" alt="Image" /></td>
</tr>
</tbody>
</table>

**Form Factor**

<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>3</th>
<th>10</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBSS</td>
<td><img src="image9.png" alt="Image" /></td>
<td><img src="image10.png" alt="Image" /></td>
<td><img src="image11.png" alt="Image" /></td>
<td><img src="image12.png" alt="Image" /></td>
</tr>
<tr>
<td>HRG</td>
<td><img src="image13.png" alt="Image" /></td>
<td><img src="image14.png" alt="Image" /></td>
<td><img src="image15.png" alt="Image" /></td>
<td><img src="image16.png" alt="Image" /></td>
</tr>
</tbody>
</table>

**Cell area (µm²)**

<table>
<thead>
<tr>
<th>0</th>
<th>3</th>
<th>10</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBSS</td>
<td><img src="image17.png" alt="Image" /></td>
<td><img src="image18.png" alt="Image" /></td>
<td><img src="image19.png" alt="Image" /></td>
</tr>
<tr>
<td>HRG</td>
<td><img src="image21.png" alt="Image" /></td>
<td><img src="image22.png" alt="Image" /></td>
<td><img src="image23.png" alt="Image" /></td>
</tr>
</tbody>
</table>

**D**

**(-) CLEC-IB Ab**

| HBSS | ![Image](image25.png) | ![Image](image26.png) | ![Image](image27.png) | ![Image](image28.png) |
| HRG 0.25µM | ![Image](image29.png) | ![Image](image30.png) | ![Image](image31.png) | ![Image](image32.png) |

**(+)**

| HBSS | ![Image](image33.png) | ![Image](image34.png) | ![Image](image35.png) | ![Image](image36.png) |
| HRG 0.25µM | ![Image](image37.png) | ![Image](image38.png) | ![Image](image39.png) | ![Image](image40.png) |

**Form Factor**

<table>
<thead>
<tr>
<th>CLEC-IB Ab</th>
<th>CLEC-1A Ab</th>
<th>CLEC-IB Ab</th>
<th>CLEC-1A Ab</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image41.png" alt="Image" /></td>
<td><img src="image42.png" alt="Image" /></td>
<td><img src="image43.png" alt="Image" /></td>
<td><img src="image44.png" alt="Image" /></td>
</tr>
</tbody>
</table>

**Cell area (µm²)**

<table>
<thead>
<tr>
<th>CLEC-IB Ab</th>
<th>CLEC-1A Ab</th>
<th>CLEC-IB Ab</th>
<th>CLEC-1A Ab</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image45.png" alt="Image" /></td>
<td><img src="image46.png" alt="Image" /></td>
<td><img src="image47.png" alt="Image" /></td>
<td><img src="image48.png" alt="Image" /></td>
</tr>
</tbody>
</table>
The inhibition of the production of pro-inflammatory cytokines is a key factor in the prevention and therapy of sepsis. Extracellular HMGB1 can activate endothelial cells through the activation of NF-κB, leading to the release of proinflammatory cytokines such as TNF-α and IL-1β (Cohen, 2002). Our results clearly demonstrated that treatment with HRG can strongly inhibit the rHMGB1-enhanced expression/secretion of IL-8, IL-6, and TNF-α (Figure 3) and NF-κB activation (Figures 4A and 4B). These findings proved that HRG regulates not only the HMGB1 release but also the subsequent inflammatory process induced by extracellular HMGB1 on endothelial cells. HMGB1 upregulated proinflammatory responses by interacting with three
Figure 7. The Inhibitory Effects of Anti-CLEC-1A Antibody on the Protective Activity of HRG on the EA.hy926 Cells

(A) CLEC-1A expression on EA.hy926 cells was confirmed with western blotting and RT-PCR at the protein and mRNA levels. (B, C) EA.hy926 cells were cultured for 12 h until confluence and then pre-incubated with 10 μg/mL CLEC-1A Ab or CLEC1B Ab or goat IgG control antibody in DMEM medium for 6 h. The cells were then stimulated with LPS for 12 h in the presence or absence of HRG (1 μM). The immunostaining of HMGB1 (B) and ICAM-1 (C) were performed.
pathogen-related pattern recognition receptors: TLR2, TLR4, and RAGE. HRG effectively suppressed the cell surface expression of all three HMGB1 receptors (Figures 4C and 4D) in endothelial cells. These results provide a likely explanation of how HRG effectively reduces the inflammatory response in rHMGB1-activated endothelial cells.

HMGB1 was recognized as a late mediator of sepsis, and the neutralization of HMGB1 or the inhibition of its release protected animals from the lethality of endotoxemia (Sama et al., 2004; Wang et al., 1999, 2001). Our results show that both LPS and rHMGB1 injection can induce the reduction of HRG in mice plasma (Figure 5A), suggesting the LPS- or rHMGB1-induced liver injury that influence the HRG production (Tsung et al., 2005; Gong et al., 2010). The supplementary treatment with HRG can effectively inhibit the HMGB1 release in LPS-injected mice and reduce inflammatory cytokine production in rHMGB1-injected mice (Figures 5B and SC). These results provide a new evidence that HRG improves the survival rate, and relieve of inflammatory symptom of septic mice may be associated with the regulation of HMGB1 signaling.

A counteracting role of HRG on DAMP/PAMP-induced responses has long been recognized (Wake et al., 2016; Kuroda et al., 2018; Nishibori et al., 2018). It is possible that HRG as a ligand-like molecule may exert its cellular function through the stimulation of unidentified receptors. We thus first examined DAMP-related receptors, i.e., macrophage-inducible C-type lectin (MINCLE) (also known as C-type lectin-like receptor 4E [CLEC4E]) (Yamasaki et al., 2008), and triggering receptor expressed on myeloid cells-1 (TREM-1) (El Mezayen et al., 2007), because ligands for these receptors have not been comprehensively identified, unlike those of the well-known DAMP receptors, toll-like receptor 4 (TLR4), and RAGE. We also investigated SIGLEC family receptors that are key modifiers of neutrophil functions (McMillan et al., 2013; Favier, 2016). Based on our screening trial using CLEC family members, CLEC-1A was observed to be the only one among a set of candidate receptor molecules that interacts with the membrane-anchored HRG that we designed to be expressed on the cell surface (Figure 6A). The results of our surface plasmon resonance experiments demonstrated that exCLEC-1A-Fc binds to HRG with high affinity (K_D value of 7 × 10^{-11} M) (Figure 6B); meanwhile, HRG binds to immobilized exCLEC-1A-Fc with K_D value of 1 × 10^{-8} M (Figure S6B). These results provide strong evidence that CLEC-1A is one of the receptors for HRG. To further confirm these results, we examined the protective effect of HRG on neutrophils and endothelial cells after blocking the CLEC-1A. The results showed that the spherical shape-inducing effects of HRG were significantly neutralized by the treatment with exCLEC-1A-Fc fusion protein (Figure 6C-a) or CLEC-1A Ab (Figure 6D-a). Moreover, pre-treatment with CLEC-1A antibody effectively prevented the inhibiting effects of HRG on LPS-induced HMGB1 translocation (Figure 7B) and HMGB1-mediated ICAM-1 expression (Figure 7C) in EA.hy926 cells. The neutralizing effect of exCLEC-1A-Fc fusion protein and the blocking effects of CLEC-1A antibody on the action of HRG on EA.hy926 cells and neutrophils further indicate that CLEC-1A may be a novel receptor for HRG.

It is worthy of mentioning that CLEC-1A might not be the sole receptor for HRG. Our previous study proved that HRG augmented natural killer cell function by modulating PD-1 expression via CLEC-1B (Nishimura et al., 2019). Stanniocalcin-2 (STC2) was also reported as an interacting partner of HRG on the surface of inflammatory cells in vitro. The colocalization of HRG and STC2 in gliomas may play a role for suppressing glialoma growth by modulating tumor inflammation through monocyte infiltration and differentiation (Roche et al., 2018). However, whether the interaction of HRG with STC2 may influence the HRG-CLEC-1A-mediated signaling need to be clarified in the future. HRG is a multidomain protein consisting of 2 N-terminal regions, a central histidine-rich region (HRR) and a C-terminal domain. HRG interacts with many ligands through various binding domains, regulating a number of biological processes. Some ligands binding to the HRR domain of HRG is dependent on Zn^{2+} or acidic pH (Sundberg and Martin, 1974; Morgan, 1981). It should be addressed in the future study, whether HRG-CLEC1A binding is modulated by Zn^{2+}.

The present study is the first report that HRG efficiently inhibited LPS-induced HMGB1 translocation and release and the HMGB1-mediated signal pathway in vascular endothelial cells through CLEC-1A receptor. These results added strong evidence to our previous observation that supplementary HRG treatment in...
septic mice can relieve the septic syndrome and prevent endothelium barrier dysfunction. The role of HRG in barrier protection may depend mainly on its effect of inhibiting HMGB1 release from endothelial cells. Our results thus not only clarify the receptor of the effects of HRG on vascular endothelial cells but also provide evidence for HRG as a treatment for sepsis.

Limitation of the Study
We proved the role of HRG on the regulation of HMGB1 signaling in endothelial cells through CLEC-1A receptor using in vitro experiments. In addition, our previous study found that the knockdown of liver HRG by siRNA could exacerbate septic inflammation and lethality compared with that in the control mice, which indicated that the depletion of HRG are more vulnerable to sepsis (Wake et al., 2016). However, the involvement of HRG and CLEC-1A in septic condition are not clarified and characterized in vivo in current research. Hrg−/− and Clec-1A−/− mice would be used in the future research. Moreover, although we proved the binding between CLEC 1A and HRG in vitro, the binding domain on HRG and the relationship with Zn2+ and PH will require additional studies.

Resource Availability
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Masahiro Nishibori (mbori@md.okayama-u.ac.jp).

Materials Availability
All unique reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

Data and Code Availability
This study did not generate/analyze (datasets/code).

METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.101180.

ACKNOWLEDGMENTS
This research was supported by grants from AMED (JP19 im0210109) and from the Secom Science and Technology Foundation to M.N., a Grant-in-Aid for Scientific Research (no.19H03408 to M.N.), a Grant-in-Aid for Young Scientists (no. 17K15580 to H.W.), and a Grant-in-Aid for Scientific Research (no. 19K07401 to K.T.) from the Japan Society for the Promotion of Science (JSPS). The author S.G. was supported by the scholarship from China Scholarship Council. We thank the Japanese Red Cross Society for providing the fresh-frozen human plasma.

AUTHOR CONTRIBUTIONS
S.G. and M.N. conceived the study, designed the experiments, analyzed data, and wrote the manuscript. H.W. edited the manuscript. S.M. and H.W. purified HRG from the human plasma. H.Z. and Y.T. performed experiments on neutrophils. D.W. and K.L. produced the recombinant HMGB1. K.T. and H.T. critically reviewed the manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.
REFERENCES


Supplemental Information

Histidine-Rich Glycoprotein Inhibits High-Mobility Group Box-1-Mediated Pathways in Vascular Endothelial Cells through CLEC-1A

Shangze Gao, Hidenori Wake, Masakiyo Sakaguchi, Dengli Wang, Youhei Takahashi, Kiyoshi Teshigawara, Hui Zhong, Shuji Mori, Keyue Liu, Hideo Takahashi, and Masahiro Nishibori
Figure S1. The effects of HRG on the TNF-α-induced HMGB1 translocation in EA.hy 926 cells, related to Figure 1. EA.hy 926 cells were incubated with HRG or phosphate-buffered saline (PBS) for 1 h before being stimulated with 100 ng/ml TNF-α for 12 h, and the translocation of HMGB1 was observed by immunostaining as described in the Methods section of the main text. HMGB1 staining (green) and nucleus staining (blue) are shown. Images are representative of three independent experiments. Scale bar = 20 μm.
Figure S2. The effects of HRG on the LPS-induced HMGB1 translocation in HMVECs, related to Figure 1. Human primary lung microvascular endothelial cells (HMVECs) were incubated with HRG or PBS for 1 h before being stimulated with 100 ng/ml LPS for 12 h, and the translocation of HMGB1 was observed by immunostaining as described in the Methods section. HMGB1 staining (green) and nucleus staining (blue) are shown. Images are representative of three independent experiments. Scale bar = 20 μm. The nuclear HMGB1 was quantified using ImageJ software. The graph results are means ± SEM (n=5 per group). One-way ANOVA followed by the post hoc Fisher test. **p<0.01 vs. control, ##p<0.01 and ++p<0.01 vs. PBS.
Figure S3. Cell viability of EA.hy 926 cells after stimulated with LPS or rHMGB1, related to Figure 1. EA.hy 926 cells were pre-incubated with HRG/HSA for 1 h before stimulation with LPS (100 ng/ml) or rHMGB1 (1 μg/ml) for 8 h. The cells were then incubated with MTT at 37°C for 4 h by adding 10 μl of 5 ng/ml MTT solution into each well. After the removal of the cell supernatant, 200 μl of DMSO was added into each well to dissolve the crystals. The OD value was recorded using microplate reader at 570 nm wavelength. All results are the means ± SEM of three different experiments.
Figure S4. HRG inhibited the reduction of HMGB1 mRNA expression induced by LPS stimulation in EA.hy 926 cells and HMVECs, related to Figure 1. Both lines of vascular endothelial cells were cultured with LPS in the presence or absence of HRG. The expression of HMGB1 at the mRNA level on the cells was measured by quantitative RT-PCR. The results were normalized to the expression of β-actin and are expressed as the means ± SEM (n=5 per group). One-way ANOVA followed by the post hoc Fisher test. **p<0.01 vs. control, ##p<0.01 and ++p<0.01 vs. PBS and HSA.
Figure S5. Effect of HRG on the rHMGB1-induced expression of cell adhesion molecules in HMVECs, related to Figure 2. Confluent endothelial cells were incubated with rHMGB1 (1 μg/ml for 16 h) after being treated with the indicated concentrations of HRG or HSA for 1h. The cell surface expression of ICAM-1 (green) on HMVEC was observed by immunostaining. Scale bars = 20 μm.
Figure S6. HRG and CLEC 1A interaction in vitro using Biacore T200, related to Figure 6.

A: The binding affinity of human recombinant exCLEC-1A protein to HRG in vitro. Purified HRG (5 μg/ml) from human plasma was immobilized on a CM5 Biacore chip, and different concentrations of the human recombinant exCLEC-1A protein (3.125, 6.25, 12.5, 25 or 50 μg/ml) were flowed at time zero for 120 sec. Surface plasmon resonance (BIAcore) showed a rapid increase in response units (RU), indicating the binding of human recombinant CLEC-1A protein to the immobilized HRG. The K_D value was determined as $4 \times 10^{-7}$ M.

B: The binding affinity of HRG to exCLEC-1A-Fc in vitro. Extracellular domain of CLEC-1A-Fc (exCLEC-1A-Fc) fusion protein (10 μg/ml) was immobilized on a CM5 sensor chip, and different concentrations of the purified HRG from human plasma (3.125, 6.25, 12.5, 25 or 50 μg/ml) were flowed at time zero for 120 sec. Surface plasmon resonance (BIAcore) showed a rapid increase in response units (RU), indicating the binding of HRG to the immobilized exCLEC-1A-Fc fusion protein. The K_D for HRG binding to exCLEC-1A-Fc was determined as $1 \times 10^{-8}$ M.
Table S1. RT-PCR primer sequences, related to Figure 3, Figure 4, Figure 7 and transparent methods.

<table>
<thead>
<tr>
<th>mRNA</th>
<th>Sense primer</th>
<th>Anti-sense primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-actin:</td>
<td>5'-AGCGGGAAATCGTGCGTG-3'</td>
<td>5'-CAGGGTACATGGTGTTGCC-3'</td>
</tr>
<tr>
<td>IL-6:</td>
<td>5'-GAACCTCTCTTCCACAAGCGCCTT-3'</td>
<td>5'-CAAAAGACCAGTGATGATTTCACCAGG-3'</td>
</tr>
<tr>
<td>IL-8:</td>
<td>5'-ATGACCTCTAGCTGGCGGCTTGCT-3'</td>
<td>5'-TCTCAGCCCTCTTCAAAAAACTTCT-3'</td>
</tr>
<tr>
<td>IL-1β:</td>
<td>5'-CAGCCATGCCAGAAGTTCT-3'</td>
<td>5'-GACATCAACAGCTTTTTTGC-3'</td>
</tr>
<tr>
<td>TNF-α:</td>
<td>5'-GAGTGACAAGCCTGTAGC-3'</td>
<td>5'-CCCTTCTCAGCTGGAAG-3'</td>
</tr>
<tr>
<td>NF-κBp65:</td>
<td>5'-GCCATGGACGAACTGTTCCC-3'</td>
<td>5'-GGGAA CAGTCGCTCCATGCG-3'</td>
</tr>
<tr>
<td>TLR-2:</td>
<td>5'-GCCAAAGTCTTGATTTGG-3'</td>
<td>5'-TTGAAGTTCTCCAGCCTCTG-3'</td>
</tr>
<tr>
<td>TLR4:</td>
<td>5'-ACTCCCTCCAGGTTCTTGATAC-3'</td>
<td>5'-CGGGAAATAAGTCTGTAGTG-3'</td>
</tr>
<tr>
<td>RAGE:</td>
<td>5'-GCCCTCCAGTACTACTCTCG-3'</td>
<td>5'-TGTTGGCCACCCATCCAG-3'</td>
</tr>
<tr>
<td>CLEC-1A:</td>
<td>5'-AAACAAAGACCTGGAAATTGC-3'</td>
<td>5'-TCTTGGGCTGGACATCTATA-3'</td>
</tr>
<tr>
<td>HMGB1:</td>
<td>5'-AGATATGGCAAAAAGCGGACAAG-3'</td>
<td>5'-TCAGAGCAAGAGAGAAGAAG-3'</td>
</tr>
</tbody>
</table>
Transparent Methods

Cell cultures

EA.hy 926 cell line (ATCC Cat# CRL-2922, RRID:CVCL_3901), a hybridoma of human umbilical vein endothelial cells (HUVECs) and the adenocarcinomic human alveolar basal epithelial cells A549, were cultured using Dulbecco's modified Eagle medium (DMEM, #D6546, Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY), 5% L-glutamine (#G7513, Sigma), and 10% penicillin/streptomycin (Gibco) in 5% CO₂ at 37°C. After reaching confluence, the EA.hy 926 cells were detached from culture flasks using 0.25% Trypsin-EDTA (Gibco), washed, and resuspended in DMEM. These cells were passaged every 3–4 days, and all experiments were performed with the cells kept in culture between three and six passages as described (Wake et al., 2016; Gao et al., 2019).

Primary human lung microvascular endothelial cells (HMVECs) were obtained from Lonza (#CC-2527; Walkersville, MD). HMVECs were cultured in EBMTM-2 Basal Medium (#CC-3156, Lonza) with the recommended supplements in the EGMTM-2MV SingleQuots Kit (#CC-4147, Lonza) in 5% CO₂ at 37°C. After reaching confluence, the endothelial cells were detached from culture flasks with Accutase® (10 ml per 75 cm²) at 37°C for 10 min, washed, and resuspended in culture medium. These cells were passaged every 3–4 days, and all experiments were performed with the cells kept in culture between three and ten passages.

Purification of HRG from human plasma

HRG was purified from human plasma by our lab as described (Mori et al., 2003). Human plasma was supplied by the Japanese Red Cross Society from the healthy volunteer's donation. The study protocol complied with the principles outlined in the Declaration of Helsinki and all subjects signed an informed consent. Briefly, human plasma was incubated with nickel-nitrilotriacetic acid (Ni-NTA) agarose (Qiagen, Hilden, Germany) for 2 h at 4°C with gentle shaking. The gel was packed into a column and washed successively with 10 mmol/L Tris-buffered saline (TBS) (pH 8.0) containing 10 mmol/L imidazole and then 10 mmol/L Tris-buffer (TB) (pH 8.0) containing 1 mol/L NaCl. Human HRG was eluted by 0.5 mol/L imidazole in 10 mmol/L TBS (pH 8.0). The protein eluate from Ni-NTA was further purified by a Mono Q column (GE Healthcare, Little Chalfont, UK) with NaCl gradient. Purified human HRG was identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting with a human HRG-specific antibody.

Immunostaining assay

EA.hy 926 cells or HMVEC cells were pretreated with various concentrations of HRG or human serum albumin (HSA) for 1 h before stimulated with LPS (Escherichia coli 0111:B4, Sigma) (25–200 ng/ml) or human recombinant HMGB1 (rHMGB1, Abnova, Taiwan) (1 μg/ml). The cells were then fixed with 4% paraformaldehyde (Wako Pure Chemical Industry, Osaka, Japan) and blocked with 10% bovine serum albumin (BSA), after which the cells were stained by anti-HMGB1 Ab (rabbit, Sigma, RRID:AB_444360), anti-NF-κB p65 Ab (rabbit, Abcam, RRID:AB_443394), anti-ICAM-1 Ab (Ms, Sigma, RRID:AB_445260), or anti-VCAM-1 Ab (#ab134047, Sigma, RRID:AB_2721053) for 1 h at 37°C followed by Alexa Fluor 488/568-labeled anti-rabbit/mouse
IgG. Cell nuclei were stained with DAPI for 5 min, and then observed using a confocal microscope (LSM 780, Carl Zeiss).

**Western blotting**

The whole cell lysate was collected with RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 mM DTT, 20 mM β-glycerophosphate, and protease/phosphatase inhibitors added immediately before use) and the cytoplasmic and nuclear extracts were collected with NE-PER Nuclear and Cytoplasmic Extraction Reagents (#78833, ThermoScientific, Rockford, IL). The mice plasma sample was collected with sample buffer. All the samples were then electrophoresed on polyacrylamide gels and transferred onto a polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA). The membrane was blocked with 10% skim milk for 1 h and incubated with rabbit anti-HMGB1 Ab (Rb, #ab18256, Sigma), anti-TLR2 Ab (Rb, #ab191458, Abcam), anti-TLR4 Ab (Rb, Abcam, RRID:AB_10561435), anti-CLEC 1 Ab (goat, #AF1704, RRID:AB_2083452), anti-HRG Ab (Rb, #GTX64492, Gen Tex) and anti-β-actin Ab (#sc-47778, Santa Cruz, RRID:AB_2714189) followed by goat anti-rabbit IgG-HRP (MBL, Nagoya, Japan) for 2 h at room temperature. The signals were visualized by the enhanced chemiluminescence HRP substrate method (Thermo Fisher Scientific, Waltham, MA). An Image Quant LAS4000 system was used for detection, and images were analyzed with ImageJ software ver. 1.51.

**Cell viability**

EA.hy 926 cells were plated in 96-well plates at 5×10^5 overnight, and then pre-incubated with HRG/HSA for 1 h before stimulation with LPS (100 ng/ml) or rHMGB1 (1 μg/ml) for 8 h. The cells were then incubated with MTT at 37°C for 4 h by adding 10 μl of 5 mg/ml MTT solution into each well. After the removal of the cell supernatant, 200 μl of DMSO was added into each well to dissolve the crystals. The absorbance of each well was measured using a microplate reader (model 680, Bio-Rad) at 570 nm wavelength, and the optical density (OD) value was recorded.

**Isolation of neutrophils**

Human neutrophils were isolated from peripheral blood obtained from healthy volunteers in accordance with ethics approval and guidelines of Okayama University and the Declaration of Helsinki. The blood was drawn from the antecubital vein. Human polymorphonuclear neutrophils (PMNs) were isolated by density gradient centrifugation over Polymorphprep™ (Axis-Shield, Oslo, Norway). Briefly, blood was layered over an equal volume of Polymorphprep and centrifuged at 500 g for 45 min at 22°C. The lower band containing neutrophils was subsequently collected and washed with PBS by centrifugation at 400 g for 10 min. The cells were counted with a hemocytometer (EKDS, Tokyo) by trypan blue dye exclusion. After the centrifugation, the pellet was resuspended in Hank’s balanced salt solution (HBSS). Purified human neutrophils were labeled with calcein-AM (green) and Hoechst 33342 (blue) for 20 min at 37°C and then washed once with PBS. Finally, the cells were resuspended in HBSS to a final concentration of 2×10^6 cells/ml.

**Neutrophil adhesion assay**
EA.hy 926 cell suspensions (5×10^5 cells/ml) were cultured in 96-well plates for 16 h until confluent for the cell adhesion assay. The monolayer was then washed with PBS and pretreated with HRG or HSA (1 μmol/L) for 1 h before being stimulated with LPS (100 ng/ml) or rHMGB1 (1 μg/ml) at 37°C in a 5% CO₂ atmosphere for 4 h. After the incubation, the cells were washed with PBS. The pre-labeled neutrophils (1×10^6 cells/ml) were then added to the stimulated endothelial monolayer and co-cultured for 1 h. The neutrophils were allowed to become adherent, and the nonadherent neutrophils were washed off. The fluorescence of the adherent cells was then measured. The percentage of adherent neutrophils was calculated as: the percentage of adherence = (adherent signal/total signal) ×100, as described (Bae et al., 2011).

RNA isolation and RT-PCR

EA.hy 926 cells or HMVEC cells were harvested and mRNA was extracted using an RNeasy mini kit (Qiagen). Complementary DNA was synthesized with a Takara RNA PCR kit ver. 3.0 (Takara Bio, Nagahama, Japan) and RT-PCR was performed with a Light Cycler (Roche, Basel, Switzerland) according to the manufacturer's instructions. The primers shown in Supplemental Table S1 were used to amplify specific cDNA fragments. The β-actin expression was used to normalize the cDNA levels.

Mice

Adult male C57BL/6N mice (22±3 g, 8 week, RRID: MGI_5658420) were purchased from SLC (Hamamatsu, Japan) and then housed in the Okayama University institutional animal units (12 h light cycle). All animal experiments were approved by the university's committee and performed according to the guidelines of Okayama University on animal experiments. The C57BL/6N mice was intravenous injected of LPS (10 mg/kg) or recombinant HMGB1 (100 μg) and then HRG or HSA in vehicle (PBS) was administered through the tail vein immediately. Each mouse was given 20 mg/kg HRG or HSA in a volume of 200 μl (i.v.). After 12 h the whole blood from mouse heart were taken and used for the following experiment (Edward et al., 2000, Gao et al. 2019).

Enzyme-linked Immunosorbent Assay (ELISA)

To determine HMGB1 levels in plasma, blood samples were collected through the mouse heart under deep anesthesia, then centrifuged for 10 min at 3000 rpm. HMGB1 was detected by using an ELISA kit (Shino-Test Co, Sagamihara, Japan), according to the manufacturer’s instructions.

Cytometric bead array (CBA)

We measured the secreted cytokines in the supernatant of cultured medium or plasma form rHMGB1-injected mice by performing CBA using a Human Soluble Protein Master Buffer Kit and cytokine Flex Set (#558264, BD Biosciences, San Jose, CA) following the manufacturer's instructions. Generally, multiple capture beads for interleukin (IL)-6, IL-8, and TNF-α were mixed together. The mixed capture beads were co-incubated with 50 μl of supernatant and detection reagent for 2 h. The beads were then washed carefully and resuspended. Samples were analyzed using a FACSCanto II system (BD Biosciences). The data were analyzed with FCAP Array

10
Plasmid constructs

We hypothesized that if we could force the secreted extracellular HRG to specifically concentrate on the cell surface at a much higher level, such abundant HRG on the plasma membrane will readily recognize and bind with its specific receptor(s). Based on this hypothesis, we designed HRG to express on the cell surface, resulting in the construction of modified HRG which we named membrane-anchored HRG (maHRG). This modified HRG has a single-pass transmembrane (TM) domain sourced from basal cell adhesion molecule (BCAM) at the C-terminus of HRG protein.

In order to efficiently express the transgenes that include maHRG and a set of candidate receptor molecules in a transient manner, we inserted cDNAs of our interest into the pIDT-SMART (C-TSC) vector (Sakaguchi et al., 2014). The prepared cDNAs were as follows: human cDNAs encoding maHRG and collected CLEC family receptors (CLEC-1A, -1B, -2A, -2B, -2C, -2D, -4A, -4C, -4D, -4E, -4F, -4G, -4M, -5A, -6A, -7B, -12A and -12B). The modified maHRG was further designed to be expressed in a C-terminal HA form. The CLEC receptors were all designed for their expression as C-terminal 3xFlag-6His-tagged forms.

Immunoprecipitation

We used HEK293T cells for the co-immunoprecipitation experiments. The cells were transiently transfected with the plasmid vector of maHRG combined with each vector containing a series of collected receptors, using FuGENE-HD (Promega, Madison, WI). After 24 h of the transfection, cell pellets were prepared and lysed by M-PER mammalian protein extraction reagent (Thermo Fisher Scientific). The lysates were then incubated with agarose beads conjugated with monoclonal anti-HA tag antibody (Sigma-Aldrich, St. Louis, MO) to pull-down the expressed maHRG. The resulting immunoprecipitates were subsequently subjected to western blotting using monoclonal anti-Flag tag antibody (Sigma-Aldrich) to detect maHRG-bound receptor candidate(s).

Surface plasmon resonance analysis (BIACore)

The extracellular domain of CLEC-1A (exCLEC-1A)-Fc fusion protein was prepared from its corresponding conditioned media from cultures of a FreeStyle™ CHO-S cell (Chinese hamster ovary cell subline; Thermo Fisher Scientific)-derived stable clone. The stably expressed clone for exCLEC-1A-Fc was established by a convenient electroporation gene delivery method using our original pSAKA-1B vector as described (Kinoshita et al., 2019). After the collection of the serum-free conditioned medium from a large-scale culture of the established CHO cell clone, recombinant exCLEC-1A-Fc protein was purified by protein-G affinity chromatography according to the manufacturer's instructions.

We analyzed the binding affinity of exCLEC-1A-Fc fusion protein or human recombinant exCLEC-1A (1704-CL-050, R&D system) to HRG with the use of a BIACore T200 instrument (GE Healthcare, GE Healthcare Life Sciences, Piscataway, NJ). First, HRG (5 μg/ml) diluted by sodium acetate buffer (pH 5.0) was immobilized on the sensor chip (Biacore sensor chip CM5). An adjacent vacant flow-cell was activated with equal amounts of 0.2 M N-ethyl-N-[3-diethylamino-
propyl]-carbodiimide and 0.05 M N-hydroxysuccinimide under the same conditions as a negative control. HBS-EP + buffer was used for the sample dilution and analysis. exCLEC-1A-Fc fusion protein at a series of concentrations (3.125, 6.25, 12.5, and 25 μg/ml) was passed over the surface sensor chip at a flow rate of 30 μl/min for 2 min, and then dissociation was allowed by the application of HBS-EP buffer. The sensor chips were regenerated by washing with 10 mM glycine-HCl (pH 2.5) for 60 sec at a flow rate of 10 μl/min.

We also analyzed the binding affinity of HRG to the immobilized exCLEC-1A-fc fusion protein. exCLEC-1A-fc fusion protein (10 μg/ml) diluted by sodium acetate buffer (pH 5.0) was immobilized on the sensor chip. Purified HRG (3.125, 6.25, 12.5, 25 and 50 μg/ml) was passed over the surface sensor chip at a flow rate of 30 μl/min for 2 min, and then dissociation was allowed by the application of HBS-EP buffer. The sensor chips were regenerated by washing with 10 mM glycine-HCl (pH 2.5) for 60 sec at a flow rate of 10 μl/min. The results were calculated after the subtraction of the control values using BIACore evaluation T200 software.

Effects of HRG on neutrophils and EA.hy 926 cells after CLEC-1A blocking

Prelabeled neutrophils were incubated with HBSS or HRG (0.25 μM) together with different concentrations of exCLEC-1A-Fc fusion protein or 10 μg/ml anti-human CLEC-1A or CLEC-1B goat polyclonal antibody (R&D Systems, Minneapolis, MN) for 1 h at 37°C. The shapes of the neutrophils were then observed under a fluorescence microscope. The cell shapes and cell sizes were analyzed by using an IN Cell Analyzer 2000 (GE Healthcare/Life Sciences, Tokyo) and IN Cell Analyzer Workstation software (GE Healthcare/Life Sciences) as described (Wake et al., 2016). The form factor (max. dia./min. dia.) and the cell area were determined in each group.

EA.hy 926 cells were pre-incubated with 10 μg/ml CLEC-1A Ab, CLEC1B Ab and goat polyclonal control IgG antibodies in DMEM medium for 6 h. The cells were then stimulated with LPS for 12 h in the presence or absence of HRG (1 μM). Immunostaining of HMGB1 and intercellular adhesion molecule (ICAM)-1 were performed as described above.

Statistical analysis

The data were analyzed with GraphPad Prism software ver. 6.01 (San Diego, CA). All values are presented as the mean ± SEM and were analyzed by an analysis of variance (ANOVA) followed by Bonferroni’s test or post hoc Fisher test when the F statistic was significant. Probability (p) values <0.05 were considered significant. At least three independent experiments were performed for all of the assays.

Supplemental References:


Mori S, Takahashi HK, Yamaoka K, Okamoto M, Nishibori M. (2003). High affinity binding of serum histidine-rich glycoprotein to nickel-nitrilotriacetic acid: The application to microquantification. Life